2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1620

Habitual Physical Activity, Sedentary Behavior and Cardiovascular Disease Risk Burden in Systemic Lupus Erythematosus (SLE)
Abstract Number: 1003

Hair Treatments and the Risk of Systemic Lupus Erythematosus: the Michigan Lupus Epidemiology & Surveillance (MILES) Program
Abstract Number: 1452

Handling of Missing Data, Protocol Violation and Performance of Intention-to-Treat Analysis in the Randomized Controlled Trials of Drug Therapy of Rheumatoid Arthritis
Abstract Number: 912

Has the Attractiveness of a Career in Rheumatology Changed for the Better? Comparison of Trends in the Rheumatology Fellowship Match from 2014 to 2017 with 2008 to 2013
Abstract Number: 289

HDL Modified with Malondialdehyde-Acetaldehyde (MAA) Is Bound and Rapidly Internalized By Human THP-1 Monocytes
Abstract Number: 255

Healing Time and Blood Perfusion By Laser Speckle Contrast Analysis in Patients with Systemic Sclerosis and Digital Ulcers
Abstract Number: 195

Health Care Costs of Patients with Systemic Lupus Erythematosus (SLE) Versus Control Patients As a Function of Disease Severity: Analysis of the Betriebskrankenkassen German Sickness Fund
Abstract Number: 1955

Health Care Provider Advice for Weight Loss Among US Adults with Arthritis, National Health Interview Survey, 2014
Abstract Number: 2267

Health Related Quality of Life in Lupus: Self-Management- a Modifiable Predictor
Abstract Number: 342

Health Related Quality of Life Is Comparable in Psoriatic Arthritis and Rheumatoid Arthritis Patients in Spite of Different Disease Activity. SF-36 Data from a Large Prospective Observational Multicentre Study
Abstract Number: 892

Health-Related Quality of Life in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Randomized Controlled Phase 3 Trial
Abstract Number: 2834

Healthcare Cost Drivers in Rheumatoid Arthritis
Abstract Number: 2812

Healthcare Resource Utilization and Costs in Patients with Systemic Lupus Erythematosus before and after Initiating Treatment with Intravenous Belimumab: A US Claims Database Analysis
Abstract Number: 1030

Healthcare Service Utilization and Costs of Certolizumab Pegol Versus Infliximab Treatment in Patients with Rheumatoid Arthritis
Abstract Number: 204

Healthcare Utilization Among Young Adults Transitioning from Pediatric to Adult Care in a Safety Net Population

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].